Papazoglou, Despoina;
Wang, Victoria;
Shanafelt, Tait D;
Lesnick, Connie;
Ioannou, Nikolaos;
De Rossi, Giulia;
Herter, Sylvia;
... Ramsay, Alan G; + view all
(2024)
Ibrutinib-based therapy reinvigorates CD8 T cells compared to chemoimmunotherapy: immune-monitoring from the E1912 trial.
Blood
, 143
(1)
pp. 57-63.
10.1182/blood.2023020554.
Preview |
Text
blood_bld-2023-020554-main.pdf Download (2MB) | Preview |
Abstract
Bruton's tyrosine kinase Inhibitors (BTKis) that target B cell receptor signaling have led to a paradigm shift in CLL treatment. BTKis have been shown to reduce abnormally high CLL-associated T cell counts and the expression of immune checkpoint receptors concomitantly with tumor reduction. However, the impact of BTKi therapy on T cell function has not been fully characterized. Here, we performed longitudinal immunophenotypic and functional analysis of pre- and on-treatment (6- and 12-months) peripheral blood samples from patients in the phase 3 E1912 trial comparing ibrutinib-rituximab to fludarabine, cyclophosphamide and rituximab (FCR). Intriguingly, we report that despite reduced overall T cell counts, higher numbers of T cells including effector CD8+ subsets at baseline and at the 6-month time-point associated with no infections and favorable progression-free survival (PFS) in the ibrutinib-rituximab arm. Assays demonstrated enhanced anti-CLL T cell killing function during ibrutinib-rituximab, including a switch from predominantly CD4+ T-cell:CLL immune synapses at baseline to increased CD8+ lytic synapses on-therapy. Conversely, in the FCR arm, higher T cell numbers correlated with adverse clinical responses and showed no functional improvement. We further demonstrate the potential of exploiting rejuvenated T cell cytotoxicity during ibrutinib-rituximab using the bispecific antibody glofitamab - supporting combination immunotherapy approaches.
| Type: | Article |
|---|---|
| Title: | Ibrutinib-based therapy reinvigorates CD8 T cells compared to chemoimmunotherapy: immune-monitoring from the E1912 trial |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1182/blood.2023020554 |
| Publisher version: | https://doi.org/10.1182/blood.2023020554 |
| Language: | English |
| Additional information: | Copyright © 2024 American Society of Hematology. Licensed under Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, non derivative use with attribution. All other rights reserved. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10179713 |
Archive Staff Only
 |
View Item |
